Pharmacologic Management of Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Diseases.

Evan S Dellon, Sandeep K Gupta

Journal: Immunology and allergy clinics of North America 2024;44(2):397-406

PMID: 38575232

Full Text on Elsevier Science View on PubMed

Abstract

Data for pharmacologic treatments for non-eosinophilic esophagitis (EoE) eosinophilic gastrointestinal diseases (EGIDs) are limited. Nevertheless, because of the increasing understanding of EGID pathogenesis, a number of medications are used to treat EGIDs, though all are currently off-label. Initial therapy generally starts with corticosteroids, and "topical" delivery is preferred over systemic due to long-term side effects. A number of other small molecules could potentially be used, ranging from allergy medications to immunosuppressants. Biologics are also being used and investigated for EGIDs and represent promising targeted therapies. Multiple therapeutic targets have also been identified, many of which overlap with EoE targets.

Address: Division of Gastroenterology and Hepatology, Department of Medicine, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, 130 Mason Farm Road, Chapel Hill, NC 27599-7080, USA. Electronic address: [email protected].; Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of Alabama at Birmingham/Children's of Alabama, 1600 7th Avenue South, Birmingham, AL 35233-1785, USA.

DOI: 10.1016/j.iac.2024.01.010

Link outs

Free resources

Medical:

https://medlineplus.gov/eosinophilicdisorders.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Eosinophilia, Esophagitis, Adrenal Cortex Hormones, Immunosuppressive Agents, Enteritis